Conjunctival nevi and melanoma: multiparametric immunohistochemical analysis, including p16, SOX10, HMB45, and Ki-67

Tatyana Milman,Qiang Zhang,SuMae Ang,David Elder,Cristiane M. Ida,Diva R. Salomao,Sara E. Lally,Jerry A. Shields,Rose A. Hamershock,Kareem Sioufi,Carol L. Shields,Ralph C. Eagle

DOI: https://doi.org/10.1016/j.humpath.2020.07.020

IF: 3.526

2020-09-01

Human Pathology

Abstract:<p>The role of p16 in the diagnosis and prognosis of conjunctival melanocytic lesions in the context of other clinical and immunohistochemical parameters has not been systematically explored.</p><p>This study was conducted to determine whether p16 is a useful parameter in the diagnosis and prognosis of conjunctival melanocytic nevi and melanoma, either independently or as a component of immunohistochemical panels. Sixty one patients underwent 61 biopsies for conjunctival melanocytic lesions between 2014-2018. Pathologic diagnoses were melanoma (n=25, 41%), nevus (n=21, 34%), and conjunctival melanocytic lesion of uncertain malignant potential (n=15, 25%). The biopsies were assessed for expression of p16, SOX10, HMB45, and Ki-67. In a multivariable model, the parameters most predictive of melanoma vs. nevus were diffuse HMB45 staining [odds ratio (OR)=45, confidence interval (CI)=4.4-457, <em>P</em>=.02] and p16 nuclear H-score<u>&lt;</u>115 [OR=9.5, CI=1.2-77; <em>P</em>=.04]. There was no association of p16 expression with melanoma thickness. Next-generation sequencing identified no <em>CDKN2A</em> mutations or copy number alterations in 12 conjunctival melanomas, including the tumors with absent p16 expression. This study demonstrates that p16 immunohistochemical stain is useful in distinguishing conjunctival melanocytic nevi from melanoma, particularly in combination with HMB45. P16 expression does not appear to correlate with <em>CDKN2A</em> status and melanoma thickness.</p>

pathology